PipelineQurient portfolio plan aims to achieve balanced innovation by strategic positioning of the R&D programs.
| Discovery | Candidate | Pre-Clinical | Phase 1 | Phase 2 | Phase 3 | |||
|---|---|---|---|---|---|---|---|---|
| Anti Cancer |
Axl/Mer/CSF1R Inhibitor (Q702) |
Immuno Oncology Mono |
||||||
| Immuno Oncology Combi Q702+Pembrolizumab (KEYTRUDA®) |
 |
|||||||
| Drug Resistant NSCLC |
||||||||
| selective CDK7 inhibitor (Q901) |
Solid Tumor |
|||||||
| Q901+Pembrolizumab (KEYTRUDA®) |
|
|||||||
| Antibiotics | Cyt bc1 Inhibitor (Telacebec, Q203) |
Drug Resistant Tuberculosis |
||||||
| Buruli ulcer | ||||||||
| Anti Inflammation |
Topical 5LO Inhibitor (Q301) |
Atopic Dermatitis |
||||||
| Oral 5LO Inhibitor |
Asthma | |||||||
| Candidate | Pre-Clinical | Phase 1 | Phase 2 | ||
|---|---|---|---|---|---|
| Axl/Mer/ CSF1R Inhibitor (Q702) |
Immuno Oncology Mono |
||||
| Immuno Oncology Combi Q702+Pembrolizumab (KEYTRUDA®) |
|
||||
| Drug Resistant NSCLC |
|||||
| Selective CDK7 Inhibitor (Q901) |
Solid Tumor |
||||
| Q901+Pembrolizumab (KEYTRUDA®) |
|
||||
| Cytbc1 Inhibitor (Telacebec, Q203) |
Drug Resistant Tuberculosis |
||||
| Buruli ulcer | |||||
| Topical 5LO Inhibitor (Q301) |
Atopic Dermatitis |
||||
| Oral 5LO Inhibitor |
Asthma | ||||